Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
Submitted by
admin
on December 5, 2017 - 6:31pm
Source:
Fierce Pharma
News Tags:
JNJ
biosimilars
Remicade
Europe
anti-TNF
Headline:
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
Do Not Allow Advertisers to Use My Personal information
